BeiGene
BGNE
#844
Rank
$20.59 B
Marketcap
$193.97
Share price
-1.36%
Change (1 day)
-29.77%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

Market capitalization of BeiGene (BGNE)

Market cap: $20.59 Billion

As of August 2022 BeiGene has a market cap of $20.59 Billion. This makes BeiGene the world's 844th most valuable company by market cap according to our data. The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding shares and is commonly used to measure how much a company is worth.

Market cap history of BeiGene from 2016 to 2022

End of year Market Cap

Year Market cap Change
2022$20.59 B-25.07%
2021$27.48 B14.39%
2020$24.03 B133.57%
2019$10.28 B23.44%
2018$8.33 B87.28%
2017$4.45 B269.44%
2016$1.20 B

End of Day market cap according to different sources

On Aug 14th, 2022 the market cap of BeiGene was reported to be:

$20.59 Billion
by Yahoo Finance
$20.59 Billion
by CompaniesMarketCap
$20.05 Billion
by Nasdaq
$20.06 Billion
by Iex Cloud

Market capitalization for similar companies or competitors

Name Market cap Market cap differencediff. Country
$1.94 B-90.56%๐Ÿ‡บ๐Ÿ‡ธ USA
$28 M-99.86%๐Ÿ‡บ๐Ÿ‡ธ USA